Lisa Myers, MD
Endocrinology, Diabetes & Metabolism · Germantown, TNNPI 1992768204
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $477,089 of the $609,057 with a category attached, or 78.3%. 58 manufacturers reported payments, led by Novo Nordisk at 34.5% of the total. Among endocrinology, diabetes & metabolism clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,344 payments — averaging $259.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$210K
- Abbott$96K
- AstraZeneca$68K
- Lilly USA, LLC$66K
- Dexcom, Inc.$55K
- Johnson & Johnson$25K
- plus $88K from 52 others
What the payments were for
- Consulting fees$11,7432%
- Speaking & faculty fees$477,08978%
- Travel & lodging$65,37911%
- Food & beverage$54,5369%
- Education$860%
- Gifts$590%
- Other$1650%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$91,058
- RYBELSUS$82,706
- FARXIGA$66,484
- FREESTYLE LIBRE 3$54,262
- MOUNJARO$43,422
- MYCAPSSA$31,166
- DEXCOM G7 GSS (161)$25,726
- INVOKANA$24,947
- FreeStyle Libre$20,127
- Vascepa$17,452
- DEXCOM G6 TRANSMITTER$16,315
- Tresiba$15,257
- FreeStyle Libre Pro$12,587
- AFREZZA$7,790
- DEXCOM G6 CGM SYSTEM$7,126
- DEXCOM STELO GLUCOSE BIOSENSOR$6,561
- CeQur Simplicity$6,263
- FreeStyle Libre 2$5,631
- DEXCOM CGM$4,528
- Korlym$1,311
How this compares
$609,057 in reported general payments places this provider in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
See all endocrinology, diabetes & metabolism providers in Tennessee →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 693 | $805,923 |
| MounjaroTirzepatide | 258 | $312,278 |
| FarxigaDapagliflozin Propanediol | 245 | $267,553 |
| TrulicityDulaglutide | 208 | $262,697 |
| JardianceEmpagliflozin | 159 | $158,135 |
| AfrezzaInsulin Regular, Human | 35 | $101,848 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 82 | $77,577 |
| MycapssaOctreotide Acetate | 15 | $72,721 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 63 | $54,062 |
| Tresiba Flextouch U-200Insulin Degludec | 66 | $45,514 |
| VascepaIcosapent Ethyl | 49 | $43,723 |
| JanuviaSitagliptin Phosphate | 45 | $43,202 |
| Tresiba Flextouch U-100Insulin Degludec | 76 | $41,996 |
| Novolog FlexpenInsulin Aspart | 158 | $32,253 |
| InvokanaCanagliflozin | 33 | $27,451 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $210,342 | $821,250754 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $65,772 | $579,418495 claims |
| AstraZenecaFarxiga | $68,197 | $267,553245 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,405 | $168,884175 claims |
| Mannkind CorporationAfrezza | $9,515 | $101,84835 claims |
| Chiesi USA, Inc.Mycapssa | $16,226 | $72,72115 claims |
| MerckJanuvia, Janumet | $454 | $54,16560 claims |
| Johnson & JohnsonInvokana | $25,298 | $27,45133 claims |
| BayerKerendia | $1,492 | $26,72032 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,195 | $19,23317 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $111 | $4,765459 claims |
| AbbVieSynthroid | $841 | $3,66455 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.
Other endocrinology, diabetes & metabolism in Germantown
- Alan CohenMemphis$1.4M
- Craig WierumNashville$1.3M
- Pascal DauphinHendersonville$925K
- Shimon HararyMemphis$735K
- Amit VoraKnoxville$579K
- Terri JerkinsNashville$567K
- Samuel Dagogo-JackMemphis$407K
- Michael CarlsonNashville$381K
- David EscalanteJellico$326K
- Kathryn DahirNashville$225K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.